Skye Bioscience, Inc. (SKYE) Key Statistics & Financial Ratios

Skye Bioscience, Inc. (SKYE) — Price $1.70 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Skye Bioscience, Inc. (SKYE). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc.

Stock Data

Price$1.70
Market Cap$7M
Enterprise Value-$564620
Beta2.87
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-0.21
Price / Book-21.05
P/S0.00
EV/EBITDA0.01
EV/Sales0.00
EV/FCF0.01
P/FCF-0.24
Earnings Yield-598.80%
FCF Yield-519.69%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-329.08%
Return on Assets-457.62%
Return on Invested Capital11242.31%
Return on Capital Employed10435.35%

Financial Health

Current Ratio0.95
Quick Ratio0.95
Cash Ratio0.70
Debt / Equity-0.07
Debt / Assets0.32%
Net Debt / EBITDA0.16
Interest Coverage-9439.02

Per-Share Data

Revenue per share0.00
Book Value per share-0.10
Cash per share2.03
FCF per share-7.82
Tangible Book Value per share-0.10
Dividend per share0.00

Related companies: ALGS · BRNS · CVM · INMB · KZR · LVTX · MRSN

Explore sector: Healthcare · Biotechnology

More sections of SKYE: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks